Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Dana-Farber Cancer Institute answers your common questions about testing for mutations in BRCA genes associated with cancer.
Researchers looking at ovarian cancer cells that resist chemotherapy hope to develop new therapeutic strategies.
The diagnosis spurred the television icon to emphasize the importance of early detection when it comes to ovarian cancer.
The response rate was nearly 50% for people with breast, colon, pancreatic and other cancers.
Higher rates of anxiety and depression are associated with higher mortality risk among women with ovarian cancer.
Using birth control correlates to a small increase in breast cancer risk but a larger, permanent drop in ovarian and endometrial cancer.
But not bearing children appears to do so.
The blood test identifies biomarkers that could make patients eligible for targeted therapies.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
Most women don’t, which is one reason gynecological cancers are so deadly.
People who inherit pathogenic mutations in either one of these genes have an increased risk of developing certain cancers.
Screening would be especially cost effective in high-income nations.
A new study has found that a microRNA may help drive the transition from normal fallopian tube cells to cancer in the ovary.
"These studies can help researchers develop new strategies to improve the care of women with the worst outcomes for this cancer.”
Cholesterol-lowering medications were associated with at least a 40% reduction in mortality.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.